Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Poxel Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Poxel's earnings have been declining at an average annual rate of -51.8%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 650.5% per year.
Anahtar bilgiler
-51.8%
Kazanç büyüme oranı
-43.4%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 30.8% |
| Gelir büyüme oranı | 650.5% |
| Özkaynak getirisi | n/a |
| Net Marj | -2,861.6% |
| Sonraki Kazanç Güncellemesi | 03 Oct 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%
Mar 27
Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?
May 07How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 16How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?
Nov 17
Gelir ve Gider Dağılımı
Poxel nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 23 | 2 | -44 | 9 | 24 |
| 31 Mar 23 | 1 | -38 | 9 | 18 |
| 31 Dec 22 | 1 | -31 | 9 | 12 |
| 30 Sep 22 | 0 | -30 | 9 | 15 |
| 30 Jun 22 | 0 | -29 | 9 | 18 |
| 31 Mar 22 | 7 | -26 | 10 | 22 |
| 31 Dec 21 | 13 | -24 | 11 | 25 |
| 30 Sep 21 | 14 | -26 | 10 | 27 |
| 30 Jun 21 | 14 | -28 | 9 | 29 |
| 31 Mar 21 | 10 | -30 | 10 | 28 |
| 31 Dec 20 | 7 | -32 | 10 | 27 |
| 30 Sep 20 | 10 | -30 | 11 | 28 |
| 30 Jun 20 | 14 | -28 | 12 | 29 |
| 31 Mar 20 | 20 | -27 | 12 | 34 |
| 31 Dec 19 | 27 | -26 | 11 | 40 |
| 30 Sep 19 | 35 | -21 | 10 | 46 |
| 30 Jun 19 | 44 | -16 | 9 | 51 |
| 31 Mar 19 | 53 | -7 | 8 | 53 |
| 31 Dec 18 | 62 | 1 | 8 | 55 |
| 30 Sep 18 | 53 | -2 | 7 | 48 |
| 30 Jun 18 | 43 | -5 | 7 | 42 |
| 31 Mar 18 | 24 | -14 | 6 | 32 |
| 31 Dec 17 | 5 | -22 | 6 | 21 |
| 30 Sep 17 | 3 | -22 | 6 | 18 |
| 30 Jun 17 | 0 | -22 | 5 | 16 |
| 31 Mar 17 | 0 | -23 | 6 | 16 |
| 31 Dec 16 | 0 | -24 | 6 | 18 |
| 30 Sep 16 | 0 | -22 | 6 | 15 |
| 30 Jun 16 | 0 | -19 | 6 | 13 |
| 31 Mar 16 | 0 | -16 | 5 | 10 |
| 31 Dec 15 | 0 | -12 | 4 | 7 |
| 30 Sep 15 | 0 | -10 | 4 | 6 |
| 30 Jun 15 | 0 | -9 | 3 | 5 |
| 31 Mar 15 | 0 | -11 | 2 | 5 |
| 31 Dec 14 | 0 | -14 | 2 | 5 |
| 30 Sep 14 | 0 | -21 | 2 | 6 |
| 30 Jun 14 | 0 | -28 | 2 | 6 |
| 31 Mar 14 | 0 | -24 | 1 | 6 |
Kaliteli Kazançlar: POXEL is currently unprofitable.
Büyüyen Kar Marjı: POXEL is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: Insufficient data to determine if POXEL's year-on-year earnings growth rate was positive over the past 5 years.
Büyüme Hızlandırma: Unable to compare POXEL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: POXEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Özkaynak Getirisi
Yüksek ROE: POXEL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.